S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
NASDAQ:CGIX

Cancer Genetics - CGIX Stock Forecast, Price & News

$0.58
-0.02 (-3.33%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.56
▼
$0.60
50-Day Range
$0.60
▼
$0.96
52-Week Range
$2.11
▼
$17.50
Volume
22,678 shs
Average Volume
2.44 million shs
Market Capitalization
$2.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CGIX stock logo

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock News Headlines

March 31, 2023 | msn.com
Canadian researchers find new gene mutation that could be linked to increased breast cancer risk
March 31, 2023 | americanbankingnews.com
Cancer Genetics (NASDAQ:CGIX) Receives New Coverage from Analysts at StockNews.com
April 2, 2023 | Vantage Point (Ad)
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
March 29, 2023 | foxnews.com
New breast cancer gene can predict likelihood of hereditary disease, study finds
March 27, 2023 | nypost.com
‘Holy grail’ of cancer detection predicts tumors a year before they form: breakthrough
March 27, 2023 | msn.com
Genetic testing: How four generations of a family have battled multiple cancers
March 25, 2023 | msn.com
Saliva: The Next Frontier In Cancer Detection
March 23, 2023 | americanbankingnews.com
StockNews.com Begins Coverage on Cancer Genetics (NASDAQ:CGIX)
April 2, 2023 | Vantage Point (Ad)
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
March 13, 2023 | msn.com
San Diego Genetic Sequencing Pioneer Illumina Fends Off Carl Icahn Proxy Bid
March 5, 2023 | benzinga.com
PROSTATE CANCER FOUNDATION-FUNDED GENETIC STUDY OF MEN OF AFRICAN ANCESTRY FINDS NEW RISK FACTORS FOR PROSTATE CANCER
March 1, 2023 | usnews.com
Is Obesity Especially Dangerous for Women at Genetic Risk for Breast Cancer?
March 1, 2023 | marketwatch.com
Latest Research on Breast Cancer Liquid Biopsy Market Report 2023-2029
February 17, 2023 | marketwatch.com
Breast Cancer Predictive Genetic Testing Market: Exploration of the Top Regions and Players with Opportunities
February 13, 2023 | wsj.com
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
February 3, 2023 | msn.com
Mayo Clinic genetic counselor discusses genetic counseling
February 3, 2023 | marketwatch.com
Genetic Technologies Shares Soar Premarket on Plans for Cancer Risk Test >GENE
January 20, 2023 | msn.com
Cancer blood test using DNA fragments brings hope for earlier detection, say researchers
January 19, 2023 | msn.com
Aussie scientists map deadly cancer genes
January 18, 2023 | marketwatch.com
Breast Cancer Predictive Genetic Testing Market [ LATEST REPORT ] Size 2023 to 2028 Type, Applications with SWOT & RISK Analysis
January 12, 2023 | msn.com
Genome sequencing solutions will help to bring precision in lung cancer therapy: GlobalData
January 10, 2023 | marketwatch.com
Breast Cancer Biomarkers Market (New Report) By 2023 Is Flourishing Throughout the World till 2028| Spread Across 118 Pages
January 9, 2023 | markets.businessinsider.com
Key Genetic Code Change Drives Common Lung Cancer Type
January 3, 2023 | msn.com
Genetic patterns could help predict chances of developing pancreatic cancer
December 29, 2022 | benzinga.com
Breast Cancer Liquid Biopsy Market Report 2022: Greater Knowledge of Early Detection and Treatment Bolsters Sector
December 15, 2022 | msn.com
The newest in gene editing: Teen beats cancer in the UK
December 12, 2022 | marketwatch.com
Breast Cancer Predictive Genetic Testing Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries Data
See More Headlines
Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGIX
CUSIP
N/A
CIK
N/A
Web
www.cancergenetics.com
Phone
(201) 479-1357
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$6.33 million
Price / Sales
0.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,085,000
Free Float
N/A
Market Cap
$2.37 million
Optionable
Not Optionable
Beta
2.72

Key Executives

  • John A. Roberts
    President, Chief Executive Officer & Director
  • Andrew D. C. LaFrence
    Chief Operating & Financial Officer
  • Robert T. Fremeau
    Chief Scientific Officer
  • Ping Yeh
    Director & Chief Innovation Officer
  • Ralf Brandt
    President-Discovery & Early Development Services

Key Competitors

View All Competitors













CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2023?

Cancer Genetics' stock was trading at $0.7025 on January 1st, 2023. Since then, CGIX stock has decreased by 17.4% and is now trading at $0.58.
View the best growth stocks for 2023 here.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $0.58.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $2.37 million and generates $6.33 million in revenue each year.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 4/2/2023 by MarketBeat.com Staff